Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen… - The Lancet, 2022 - thelancet.com
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …
被引用次数：59 相关文章

[引用][C] Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase …

S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen… - The Lancet, 2022 - cir.nii.ac.jp
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for
advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial | CiNii Research CiNii …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen… - The Lancet, 2022 - thelancet.com
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

S Kim, E Wuthrick, D Blakaj, Z Eroglu… - The …, 2022 - ohiostate.elsevierpure.com
Background: Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen… - The Lancet, 2022 - Elsevier
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.

S Kim, E Wuthrick, D Blakaj, Z Eroglu… - Lancet (London …, 2022 - europepmc.org
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

S Kim, E Wuthrick, D Blakaj, Z Eroglu… - Lancet (London …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.

S Kim, E Wuthrick, D Blakaj, Z Eroglu… - Lancet (London …, 2022 - europepmc.org
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …